logo

For the Inventor, By the Inventor

Biot, France

Gilles Ouvry

This inventor holds 8 USPTO granted patents and 2 published patent applications and 5 EPO patents. Top assignee: Galderma Research & Development. Active years: 2019-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gilles Ouvry. Retrieved from https://idiyas.com/inventor/gilles-ouvry

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 

% Patents Active = 62.5

 

Average Co-Inventor Count = 4.2

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:

goldMedal8 out of 222 
 
Galderma Research & Development
 patents

Years Active: 2019-2023

Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents
1. 11731973 - Substituted pyrazolo[3,4-d]pyrimidines as mTOR inhibitors (2023-08-22),
2. 11518767 - MTOR inhibitor compounds (2022-12-06),
3. 10752617 - Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (T)) (2020-08-25),
4. 10618890 - Benzimidazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (T)) (2020-04-14),
5. 10556883 - Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine and cosmetics (2020-02-11),
6. 10550110 - Tetrahydroquinoline sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (t)) (2020-02-04),
7. 10457637 - Benzenesulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (RORγ(T)) (2019-10-29),
8. 10246440 - Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR γ (T)) (2019-04-02),

Title: The Innovative Contributions of Gilles Ouvry

Introduction

Gilles Ouvry is a prominent inventor based in Biot, France, known for his significant contributions to the field of pharmaceutical research. With a total of eight patents to his name, Ouvry has made remarkable strides in developing novel compounds that target critical biological pathways.

Latest Patents

Among his latest patents are the "Substituted pyrazolo[3,4-d]pyrimidines as mTOR inhibitors." This invention relates to novel mTOR inhibitor compounds characterized by a specific formula, along with their pharmaceutically acceptable salts. The patent also covers compositions that include these mTOR inhibitor compounds, methods for their production, and their potential uses in therapeutic applications. Another notable patent is focused on mTOR inhibitor compounds with a general formula, emphasizing their role in drug compositions and methods of production.

Career Highlights

Gilles Ouvry is currently associated with Galderma Research & Development, where he continues to push the boundaries of innovation in drug development. His work has been instrumental in advancing treatments that target mTOR pathways, which are crucial in various diseases, including cancer.

Collaborations

Ouvry collaborates with talented professionals in his field, including Etienne Thoreau and Branislav Musicki. These partnerships enhance the research and development process, fostering an environment of creativity and innovation.

Conclusion

Gilles Ouvry's contributions to pharmaceutical research and his innovative patents underscore his role as a leading inventor in the industry. His work continues to pave the way for new therapeutic options, demonstrating the impact of dedicated research and collaboration in advancing medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…